SCHEMBL2062909

SCHEMBL2062909

CC(C)(C)OC(=O)N1CCC(c2nc(-c3ccccc3)c[nH]2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 3/20 0.58
GPR119 Q8TDV5 4/20 0.50
HTT P42858 2/20 0.50
NAMPT P43490 1/20 0.47
PRMT5 O14744 2/20 0.47
USP30 Q70CQ3 2/20 0.47
CKS1B P61024 1/20 0.47
SKP1 P63208 1/20 0.47
SKP2 Q13309 1/20 0.47
KDM4E B2RXH2 2/20 0.46
THRB P10828 2/20 0.46
MAPT P10636 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
CRHBP P24387 1/20 0.46
KMT2A Q03164 1/20 0.46
CRHR2 Q13324 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6167211 0.98 HPGDS (0.56) HPGDSGPR119HTTNAMPTPRMT5
SCHEMBL2834170 0.91 HPGDS (0.70) HPGDSGPR119PRMT5USP30CKS1B
SCHEMBL6168833 0.89 HTT (0.51) HPGDSGPR119HTTKDM4ETHRB
SCHEMBL27776225 0.89 HPGDS (0.49) HPGDSGPR119HTTNAMPTUSP30
SCHEMBL310851 0.89 SMN1; SMN2 (0.49) HPGDSHTTUSP30KDM4ETHRB
SCHEMBL27797117 0.87 P2RY14 (0.53) HPGDSGPR119HTTKDM4EMAPT
SCHEMBL311477 0.87 HPGDS (0.48) HPGDSGPR119HTTKDM4ETHRB
SCHEMBL2839026 0.85 HPGDS (0.71) HPGDSGPR119PRMT5USP30CKS1B
SCHEMBL2835494 0.85 HPGDS (0.71) HPGDSGPR119PRMT5USP30CKS1B
SCHEMBL2835501 0.85 HPGDS (0.71) HPGDSGPR119PRMT5USP30CKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102216302-B Akt and p70 s6 kinase inhibitors LILLY CO ELI 2013-08-21 CN disclosed
EP-2358710-B1 AKT AND P70 S6 KINASE INHIBITORS LILLY CO ELI (US) 2012-08-15 EP disclosed
US-8148387-B2 AKT and P70 S6 kinase inhibitors ELI LILLY AND COMPANY (US) 2012-04-03 US disclosed
CN-102216302-A Akt and p70 s6 kinase inhibitors LILLY CO ELI 2011-10-12 CN disclosed
US-20100120801-A1 AKT AND P70 S6 KINASE INHIBITORS ELI LILLY AND COMPANY 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120801-A1 AKT AND P70 S6 KINASE INHIBITORS RPS6KA6, RPS6KA1, MTOR HPGDS 2433/4885GPR119 1116/4885HTT 1836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.